We came across a bullish thesis on CureVac N.V. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CVAC. CureVac N.V.'s share was trading at $5.20 as of December 1st. CVAC’s trailing and forward P/E were 8.30 and 5.24 respectively according to Yahoo Finance.
[caption id="attachment_622670" align="aligncenter" width="750"]CureVac (CVAC) represents the most credible non-U.S. mRNA platform positioned for “toll-road” economics through foundational IP and process know-how that others may need to license....
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.